RESEARCH

TT-01

 

Features:

Novel immune epitopes.

Pipeline

Pre-Clinical

Pre-Clinical

ADC mechanism-1.png

 TT-01 

Antibody-Drug Conjugates

Features:

Syngeneic mouse models show that mTT-01 ADC led to complete regression of tumors in 83% of mice, and better survival rate.

 
CAR-108 mechanism (public).jpg

 CAR-108 

CAR-T Cell Therapy

Features:

The CAR-T cell therapy was developed using the TT-01 sequence that can accurately identify glycosylated antigen as a template.


In the cell-based experiments, it has been proven that CAR-108 can kill 80% of tumor cells effectively.

​In the in vivo animal study, the tumor was totally remission after CAR-T treatment.